Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Meera K. Ladani"'
Autor:
Namrata Prajapati, Poonam Giri, Prashant Delvadia, Shyamkumar Giri, Nuggehally R. Srinivas, Nirmal Patel, Vipul Joshi, Mukul R. Jain, Meera K. Ladani
Publikováno v:
Xenobiotica. 50:815-821
Recent approvals of beta-lactamase inhibitor (BLI) drug in combination with cephalosporins/penems have provided the right impetus for novel BLIs. One important research question, hitherto not addressed, is pertaining to the relevance of preclinical p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4295177df9137e567e4488c2b4345c2c
https://doi.org/10.1080/00498254.2019.1696494
https://doi.org/10.1080/00498254.2019.1696494
Autor:
Prashant Delvadia, Poonam Giri, Namrata Prajapati, Vipul Joshi, Shyamkumar Giri, Pankaj R. Patel, Mukul R. Jain, Nuggehally R. Srinivas, Meera K. Ladani, Nirmal Patel, Lakshmikant Gupta
Publikováno v:
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 130
Saroglitazar, a PPAR αҮ agonist, is currently undergoing global development for the treatment of NASH and other indications. Saroglitazar showed CYP2C8 inhibition in human liver microsomes (IC50: 2.9 μM). The aim was to carry out drug-drug interac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06fff7701d6d680698ff0fe118f5516d
https://pubmed.ncbi.nlm.nih.gov/30633968
https://pubmed.ncbi.nlm.nih.gov/30633968